Alector, Inc. (ALEC): Operating Cash Flow
-$184.03M
Year ended 2025-12-31
-$158.23M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$184.03M | n/m | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | -$229.91M | n/m | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | -$184.16M | n/m | 2025-02-26, From 2023-01-01 |
| 2022-12-31 | -$20.33M | n/m | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $298.55M | n/m | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | -$166.73M | n/m | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | -$99.31M | n/m | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $127.46M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$17.77M | n/a | 2020-03-24, From 2017-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Alector, Inc. (ALEC) | 2025-12-31 | -$184.03M | n/m |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | -$69.17M | n/m |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | -$88.89M | n/m |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | -$22.59M | n/m |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | -$235.46M | n/m |
| Scilex Holding Co (SCLX) | 2025-12-31 | $3.82M | -80.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$18.92M | n/m |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | -$65.84M | n/m |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | -$85.62M | n/m |
Compare ALEC, LENZ, MGX, PTHS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗